Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

Rogalińska,Małgorzata; Błoński,Jerzy Z.; Góralski,Paweł; Wawrzyniak,Ewa; Hartman,Mariusz; Rogalska,Aneta; Robak,Paweł; Koceva‑Chyła,Aneta; Piekarski,Henryk; Robak,Tadeusz; Kiliańska,Zofia M.

doi:10.3892/ijo.2015.2823

Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

Authors:
- Małgorzata Rogalińska
- Jerzy Z. Błoński
- Paweł Góralski
- Ewa Wawrzyniak
- Mariusz Hartman
- Aneta Rogalska
- Paweł Robak
- Aneta Koceva‑Chyła
- Henryk Piekarski
- Tadeusz Robak
- Zofia M. Kiliańska
View Affiliations

Affiliations: Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland, Department of Hematology, Medical University of Lodz, Lodz, Poland, Department of Physical Chemistry, Faculty of Chemistry, University of Lodz, Lodz, Poland, Department of Thermobiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland, Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland
Published online on: January 8, 2015 https://doi.org/10.3892/ijo.2015.2823
Pages: 1259-1267

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To improve the efficacy of therapeutic options in chronic lymphocytic leukemia (CLL) an in vitro system to determine the response of mononuclear blood cells from blood of patients was elaborated. The study combines four approaches, i.e., cell viability, apoptosis rate, differential scanning calorimetry (DSC), and immunoblotting to develop personalized therapy protocols based on the cell sensitivity to drug exposure of individual CLL patients. The complementary analyses were performed on 28 peripheral blood samples from previously untreated CLL patients before therapy. The induction and progress of apoptosis in CLL cells exposed in vitro to purine analogs combined with mafosfamide, i.e., cladribine + mafosfamide (CM) and fludarabine + mafosfamide (FM) were assessed using the above approaches. The changes in thermal profiles (decrease/loss of transition at 95±5˚C) coincided with an accumulation of apoptotic cells, a decrease in the number of viable cells, and differences in the expression of the apoptosis‑related protein PARP‑1. No significant changes were observed in the thermal profiles of nuclei isolated from CLL cells resistant to the treatment. The complementary assays revealed a strong relationship between both the in vitro sensitivity of leukemia cells to drugs and the clinical response of the patients, determined usually after the sixth course of treatment (after ~6 months of therapy). As a summary of studies followed by complementary tests, our findings demonstrate the value of in vitro exposure of CLL cell samples to drugs intended to treat CLL patients, before their administration in order to recommend the most suitable and effective therapy for individual patients.

View Figures

View References

1	Oscier D, Dearden C, Erem E, et al: Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 159:541–564. 2012.PubMed/NCBI
2	Hallek M: Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 88:803–816. 2013. View Article : Google Scholar : PubMed/NCBI
3	Klein U and Dalla-Favera R: Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 8:22–33. 2008. View Article : Google Scholar
4	Zenz T, Mertens D, Döhner H and Stilgenbauer S: Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 25:131–137. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rogalińska M and Kilianska ZM: Targeting Bcl-2 in CLL. Curr Med Chem. 19:5109–5115. 2012. View Article : Google Scholar
6	Martin-Subero JI, López-Otín C and Campo E: Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr Opin Hematol. 20:362–368. 2013. View Article : Google Scholar : PubMed/NCBI
7	Chiorazzi N: Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2012:76–87. 2012.PubMed/NCBI
8	Rodriquez-Vicente AE, Díaz MG and Hernández-Rivas JM: Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet. 206:49–62. 2013. View Article : Google Scholar
9	Oppezzo P and Dighiero G: Role of B-cell receptor and the microenvironment in chronic lymphocytic leukemia. Blood Cancer J. 3:e1492013. View Article : Google Scholar
10	Robak T: Application of new drugs in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2:e20100112010. View Article : Google Scholar : PubMed/NCBI
11	Rogalińska M and Kiliańska ZM: Potential new agents for chronic lymphocytic leukemia treatment. Anticancer Agents Med Chem. 10:666–682. 2010. View Article : Google Scholar
12	Qiu LN, Zhou YL, Wang ZN, Huang Q and Hu WX: ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells. Int J Oncol. 41:533–540. 2012.PubMed/NCBI
13	Chen R and Plunkett W: Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukemia. Best Pract Res Clin Haemat. 23:155–166. 2010. View Article : Google Scholar
14	Bosanquet AG, Richards SM, Wade R, et al: Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukemia by an enhanced method of individualised tumour response testing. Br J Haematol. 146:384–395. 2009. View Article : Google Scholar : PubMed/NCBI
15	Rogalinska M, Blonski J, Góralski P, et al: Usefulness of differential scanning calorimetry for monitoring ex vivo the changes in responses of CLL cells to anticancer drugs: development of personalized therapy. Blood (ASH Annual Meeting abstracts). 116:46352010.
16	Riches JC, Ramsay AG and Gribben JG: Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy. Curr Pharm Des. 18:3389–3398. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zenz T, Gribben JG, Hallek M, et al: Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 119:4101–4107. 2012. View Article : Google Scholar : PubMed/NCBI
18	Rogalińska M, Franiak-Pietryga I, Błoński JZ, et al: Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases. Cancer Biol Ther. 14:6–12. 2013. View Article : Google Scholar
19	Balbi C, Abelmoschi ML, Gogioso L, et al: Structural domains and conformational changes in nuclear chromatin: a quantitative thermodynamic approach by differential scanning calorimetry. Biochemistry. 28:3220–3227. 1989. View Article : Google Scholar : PubMed/NCBI
20	Allera C, Lazzarini G, Patrone E, et al: The condensation of chromatin in apoptotic thymocytes shows a specific structural change. J Biol Chem. 272:10817–10822. 1997. View Article : Google Scholar : PubMed/NCBI
21	Almagor M and Cole RD: Differential scanning calorimetry of nuclei as a test for the effects of anticancer drugs on human chromatin. Cancer Res. 49:5561–5566. 1989.PubMed/NCBI
22	Rogalińska M, Góralski P, Kobylińska A, et al: Changes in leukemic cell nuclei revealed by differential scanning calorimetry. Leuk Lymphoma. 46:121–128. 2005. View Article : Google Scholar
23	Góralski P, Rogalińska M, Błoński JZ, et al: The differences in thermal profiles between normal and leukemic cells exposed to anticancer drug evaluated by differential scanning calorimetry. J Therm Anal Calorim. 118:1339–1344. 2014. View Article : Google Scholar
24	Rogalinska M, Goralski P, Wozniak K, et al: Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia. Leuk Res. 33:308–314. 2009. View Article : Google Scholar
25	Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87:4990–4997. 1996.PubMed/NCBI
26	Robak T, Blonski JZ, Gora-Tybor J, et al: Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of Polish Adult Leukemia Group (PALG CLL2). Blood. 108:473–479. 2006. View Article : Google Scholar : PubMed/NCBI
27	Kotkowska A, Wawrzyniak E, Blonski JZ, Robak T and Korycka-Wolowiec A: Chromosomal aberrations in chronic lymphocytic leukemia detected by conventional cytogenetics with DSP30 as a single agent: comparison with FISH. Leuk Res. 35:1032–1038. 2011. View Article : Google Scholar : PubMed/NCBI
28	Rogalińska M, Błoński JZ, Komina O, et al: R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. J Cell Biochem. 109:217–235. 2010. View Article : Google Scholar
29	Kobylinska A, Bednarek J, Blonski JZ, et al: In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. Oncol Rep. 16:1389–1395. 2006.PubMed/NCBI
30	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
31	Gasiorowski B, Brokos A, Kulma A, Ogorzałek A and Skórkowska K: A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytes cultured in the presence of four antimutagens. Cell Biol Mol Lett. 6:141–159. 2001.
32	Houlston RS, Catovsky D and Yuille MR: Genetic susceptibility to chronic lymphocytic leukemia. Leukemia. 16:1008–1014. 2002. View Article : Google Scholar : PubMed/NCBI
33	Abrisqueta P, Crespo M and Bosch F: Personalizing treatment for chronic lymphocytic leukemia. Expert Rev Hematol. 4:27–35. 2011. View Article : Google Scholar : PubMed/NCBI
34	Robak T, Jamroziak K, Gora-Tybor J, et al: Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclo-phospahamide as a first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 study). J Clin Oncol. 28:1863–1869. 2010. View Article : Google Scholar : PubMed/NCBI
35	Decker T, Hipp S, Ringshausen I, et al: Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 101:278–285. 2003. View Article : Google Scholar
36	Van den Neste E, Cardoen S, Offner F and Bontemps F: Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: Fludarabine and cladribine (Review). Int J Oncol. 27:1113–1124. 2005.PubMed/NCBI
37	Wierda WG, Kipps TJ, Mayer J, et al: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 28:1749–1755. 2010. View Article : Google Scholar : PubMed/NCBI
38	Sieklucka M, Pozarowski P, Bojarska-Junak A, et al: Apoptosis in B-CLL: The relationship between higher ex vivo spontaneous apoptosis before treatment in III–IV Rai stage patients and poor outcome. Oncol Rep. 19:1611–1620. 2008.PubMed/NCBI
39	Matutes E, Bosanquet AG, Wade R, et al: The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry. Leukemia. 27:507–510. 2013. View Article : Google Scholar :
40	Nagourney RA, Evans SS, Messenger JC, Su YZ and Weisenthal LM: 2 Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer. 67:10–14. 1993. View Article : Google Scholar : PubMed/NCBI
41	Shen M, Zhang Y, Saba N, et al: Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One. 8:e752522013. View Article : Google Scholar : PubMed/NCBI